Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zelos Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Zelos Therapeutics is developing a next-generation analog of parathyroid hormone for the treatment of osteoporosis and other indications.

You may also be interested in...



Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Science Matters: Glimmers Of Hope For Treating ALS

Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.

Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom

No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel